Test the assumptions behind COLL. The free valuation preview needs no sign-up. The full Studio download is planned at $19 once.
Try the free previewCollegium Pharmaceutical, Inc. (COLL) trades above the fair value estimate shown here. At $28.23 versus a $27.40 estimate, that is a 3% downside.
- Price
- $28.23
- Fair value estimate
- $27.40
- Upside
- -3%
- Forward P/E
- 4.0×
- Market cap
- $917M
- P/S (TTM)
- 1.1×
Collegium Pharmaceutical, Inc.
Overview
Thesis
Key Metrics
Valuation
| Year | P/E | P/S | EV/EBITDA |
|---|---|---|---|
| FY23 | 20.4× | 1.7× | 4.2× |
| FY24 | 13.0× | 1.4× | 4.7× |
| FY25 | 23.4× | 1.9× | 4.7× |
| TTM · | 19.1× | 1.1× | 4.8× |
| Ticker | Mkt Cap | P/E | P/S | EV/EBITDA | Rev Growth | Gross Mgn | Net Mgn |
|---|---|---|---|---|---|---|---|
| COLL | $0.92B | 19.1× | 1.1× | 4.8× | +14.3% | 60.0% | 5.9% |
| SUPN | $2.81B | – | 3.4× | 22.4× | +32.4% | 72.9% | -13.2% |
| AMPH | $0.89B | 12.4× | 1.2× | 6.6× | +5.4% | 47.7% | 10.8% |
| ANIP | $1.76B | 16.7× | 1.8× | 9.0× | +25.9% | 60.4% | 11.1% |
| PCRX | $0.92B | 65.7× | 1.2× | 9.1× | +6.2% | 79.2% | 2.0% |
Financials
| Line Item | Q2 2025 | Q2 2026 | YoY |
|---|---|---|---|
| Product Revenue, net ADHD $59.0M (JORNAY PM $46.1M, AZSTARYS $12.9M for 49 days) + pain $140.9M | $188.0M | $199.9M | +6.3% |
| Gross Profit Gross margin 57.7% to 55.2%, struck after amortisation of product rights | $108.4M | $110.3M | +1.8% |
| Amortisation of intangibles Rises with the AZSTARYS purchase price allocation, on only 49 days of ownership | $55.5M | $63.0M | +13.5% |
| Operating Expenses Includes $24.1M of acquisition-related expense and $14.5M of stock compensation | $73.3M | $106.6M | +45.5% |
| GAAP Income from Operations | $35.1M | $3.7M | -89.5% |
| Interest Expense Before a full quarter of the $300M delayed-draw term loan | $20.5M | $19.5M | -4.6% |
| GAAP Net Income Loss per share $0.46 against diluted earnings of $0.34 a year earlier | $12.0M | -$15.1M | n/m |
| Adjusted EBITDA (non-GAAP) Excludes amortisation, stock compensation, acquisition costs and inventory step-up | $105.1M | $113.8M | +8.4% |
| Line Item | Dec 31 2025 | Jun 30 2026 | Change |
|---|---|---|---|
| Cash & Equivalents Marketable securities went from $155.4M to nil, sold to help fund the acquisition | $231.3M | $129.5M | -44% |
| Current Assets Current ratio 1.03 | $691.4M | $608.0M | -12.1% |
| Goodwill From the AZSTARYS purchase price allocation | $145.9M | $190.2M | +30.3% |
| Intangible Assets, net Gross $2,221.2M less accumulated amortisation $1,035.1M | $669.5M | $1,186.1M | +77.2% |
| Total Assets | $1,656.8M | $2,135.8M | +28.9% |
| Total Borrowings Term notes $852.8M carrying, plus 2.875% convertible notes due 2029, $238.7M carrying | $809.3M | $1,091.6M | +34.9% |
| Deferred Royalty Obligation Assumed in the 2024 Ironshore acquisition, fair value $142.6M. Outside the borrowings figure above | $121.6M | $121.4M | -0.2% |
| Contingent Consideration Fair value of the AZSTARYS milestone earn-out, which can reach $135M | – | $38.5M | n/m |
| Shareholders' Equity Book value is 34% of the market capitalisation | $301.7M | $311.9M | +3.4% |
| Line Item | H1 2025 | H1 2026 | YoY |
|---|---|---|---|
| Operating Cash Flow Flat, and struck before the acquisition contributed a full quarter | $127.8M | $128.4M | +0.5% |
| Capital Expenditure The company owns almost no fixed assets, so free cash flow is close to operating cash flow | $0.9M | $0.8M | -11.2% |
| Acquisition of AZSTARYS Net of cash acquired, funded $355.6M from cash and $300M from the delayed-draw term loan | – | $655.4M | n/m |
| Trailing 12M Free Cash Flow 35.8% of the market capitalisation. Enterprise value is 5.7 times it | – | $328.3M | n/m |
Catalysts
Risks
| Risk | Category | Severity | Probability | Impact on Thesis |
|---|---|---|---|---|
| Adjusted EBITDA guidance for 2026 of $445-470M sits below the $460.5M the company actually earned in fiscal 2025, and that guidance already includes AZSTARYS from 12 May. The $655.6M acquisition has added $539.5M to net debt and, on management's own forecast, nothing yet to group earnings. | Capital Allocation | High | Certain | The central risk on this page, and not a matter of interpretation, because both figures are the company's own. The bull case does not need the market to re-rate the shares; it needs 2027 to show the acquired product actually lifting group profit past where it was before the money was spent. Until a quarter demonstrates that, the enterprise value being unchanged since the year-end is the market agreeing with guidance rather than ignoring an asset. |
| The company states that as of 1 April 2022 it focused entirely on commercial products rather than research and development, and that no research and development expense has been incurred since the quarter ended 31 March 2022. Amortisation of purchased product rights ran $229.4M over the trailing twelve months, 28.4% of revenue, and is excluded from both GAAP EBITDA and adjusted EBITDA. | Earnings Quality | High | Certain | A company that no longer develops products must buy them to replace them, and it has just spent $655.6M doing exactly that. Amortisation is the record of what it has paid. Paying a multiple of a measure that excludes it, on a business with no research budget, is how a debt-funded roll-up is mistaken for a cash machine. Xtampza ER, on the company's own DETERx platform, is the last product it created itself and is 22.5% of the most recent quarter's revenue. |
| Pain revenue fell 9% year over year to $140.9M and remains 70% of the total. Nucynta fell 24% to $35.2M and Xtampza ER fell 14% to $45.0M. The guidance cut was attributed largely to lower net pricing on the authorised-generic versions of Nucynta. | Revenue Decline | High | Likely | Price erosion in generics rarely reverses. The base case needs ADHD growth to cover this decline, which it did at the revenue line this quarter, but only with 49 days of an acquired product included. If the pain decline accelerates from 9% toward the 24% the Nucynta line is running at, the growth rate the bull case assumes is not sufficient. |
| Borrowings are $1,091.6M carrying value against $129.5M of cash, with no marketable securities remaining. Net debt is $962.1M, 105% of the market capitalisation and 2.0 times trailing adjusted EBITDA. The credit agreement carries a first lien secured net leverage maintenance covenant permitting netting of only $250M of unrestricted cash, plus a fixed charge coverage covenant, tested quarterly. | Debt Load | High | Certain | The interest spread of SOFR plus 2.75% to 3.75% is set by that same ratio, so a shortfall against guidance raises the cost of debt at the moment the covenant tightens. The filings disclose that the covenants exist but not the thresholds or current headroom, so an outside reader cannot size the cushion. The equity is 48.8% of enterprise value, which means a 10% move in enterprise value is a 20.5% move in the share price in either direction. |
| The second quarter produced a GAAP net loss of $15.1M and a loss per share of $0.46, while the non-GAAP adjusted figures were net income of $75.4M and $1.92 per share. The forward multiple near 4 times that data providers report is computed against the adjusted figure. | Reported vs Adjusted | medium | Certain | A screener surfaces this company at about four times forward earnings. The reported result for the most recent quarter is a loss, and the $90.5M difference is mostly $63.0M of amortisation and $24.1M of acquisition-related expense. Both figures describe the same company. A reader who acts on the first without seeing the second is not looking at the business. |
| Net debt of $962.1M counts borrowings only. The balance sheet also carries a deferred royalty obligation of $121.4M, assumed in the 2024 Ironshore acquisition and disclosed at a fair value of $142.6M, plus $38.5M of contingent consideration and $29.7M of business combination consideration payable. | Obligations | medium | Certain | Every multiple on this page uses the borrowings-only figure, because that is the basis the historical comparisons are built on and mixing bases is how the first version of this page went wrong. A reader who counts the royalty obligation as debt should use net debt of $1,083.4M and enterprise value of $2,000.9M, which moves enterprise value to adjusted EBITDA from 3.93 times to 4.19 times and makes the shares look dearer, not cheaper, against their own history. |
| Institutional ownership is not published as a figure on this page. The data feed returns a value above 100% of shares outstanding for this company, which cannot describe a share register, and no figure has been substituted for it. | Data Integrity | Low | Certain | Ownership concentration matters for a company with a 32.2 million share float and 18.7% short interest, and the honest position is that this page cannot source it reliably. The insider figure of 1.2% and the short interest come from the same feed and sit within possible ranges, but all three should be read as indicative rather than filed. |
Technical Snapshot
Ownership & Insider Activity
Peer Comparison
| Ticker | Mkt Cap | P/E | P/S | EV/EBITDA | Rev Growth | Gross Mgn | Net Mgn |
|---|---|---|---|---|---|---|---|
| COLL | $0.92B | 19.1× | 1.1× | 4.8× | +14.3% | 60.0% | 5.9% |
| SUPN | $2.81B | – | 3.4× | 22.4× | +32.4% | 72.9% | -13.2% |
| AMPH | $0.89B | 12.4× | 1.2× | 6.6× | +5.4% | 47.7% | 10.8% |
| ANIP | $1.76B | 16.7× | 1.8× | 9.0× | +25.9% | 60.4% | 11.1% |
| PCRX | $0.92B | 65.7× | 1.2× | 9.1× | +6.2% | 79.2% | 2.0% |
Research Notes
Sources
Collegium Pharmaceutical, Inc. valuation questions
Is Collegium Pharmaceutical, Inc. (COLL) stock undervalued?
Against the fair value estimate shown on this page, Collegium Pharmaceutical, Inc. trades above: $28.23 today versus a $27.40 estimate, about -3%. The methodology and per-scenario sources are set out in the Valuation section. Treat it as research, not advice, and do your own homework.
What is Collegium Pharmaceutical, Inc.'s fair value?
The fair value estimate shown for COLL is $27.40. Its valuation scenarios span bear $18.20, base $27.40, bull $39.75. See the Valuation section for the basis of each.
What is Collegium Pharmaceutical, Inc.'s forward P/E ratio?
Collegium Pharmaceutical, Inc. (COLL) trades at a forward P/E of 4.0×, and 1.1× trailing sales.
What is Collegium Pharmaceutical, Inc.'s market cap?
Collegium Pharmaceutical, Inc. (COLL) has a market capitalization (its market value, often searched as "net worth") of $917M, and an enterprise value of $1.88B.
What is the bull and bear case for COLL?
Valuation scenarios: bull $39.75, base $27.40, bear $18.20. Each reflects a distinct set of assumptions; the drivers and sources are detailed in the Valuation section above.